Skip to main content

Overview

The specific aims of my recent research are to use ultrastructural and functional approaches to determine whether reactive oxygen species (ROS) are involved in Angiotensin II (AngII) signaling in well-characterized central autonomic neurons and to define their enzymatic source to determine whether NADPH oxidase is present in central autonomic neurons and, if so, whether NADPH oxidase-derived ROS are involved in the effects of AngII on these neurons. These studies focused on the dorsomedial nucleus of the solitary tract (dmNTS) because this region receives afferents from arterial baroreceptors and cardiopulmonary receptors via the vagus nerve, and is critical for maintaining cardiovascular homeostasis. Using double-label immunoelectronmicroscopy we have found that the essential NADPH oxidase subunit gp91phox is present in NTS neurons receiving vagal-like afferents that also contain AT1 receptors. In parallel experiments using electrophysiological approaches of dissociated dmNTS neurons anterogradely labeled via the vagus, I have found that AngII potentiates the L-type Ca2+ currents, an effect mediated by AT1 receptors and abolished by the ROS scavenger MnTBAP. The NADPH oxidase assembly inhibitor apocynin and the peptide inhibitor gp91ds, but not its scrambled version, also blocked the potentiation. The results provide evidence that NADPH oxidase-derived ROS are involved in the effects of AngII on Ca2+ signaling in dmNTS neurons receiving vagal afferents, and support the notion that ROS are important signaling molecules in central autonomic networks.  For more information, please visit our website at:http://www.cornellneurology.org/neurobiology

Highlights

  1. 1
    Neuroscience · 2022
    PMID: 34999197PMCID: PMC9116447DOIFirst author8 citations

Publications

78 publications

Active

5 grants
  • Co-I
    Alzheimer Pathology and Neurovascular Dysfunction
    National Institute of Neurological Disorders and Stroke · 2017–2027· 2 renewals
    R01NS037853-27
  • Co-I
    Dietary sodium, neurovascular dysfunction and cerebrovascular risk
    National Institute of Neurological Disorders and Stroke · 2015–2027· 2 renewals
    R01NS095441-06
  • Co-I
    ApoE4, neurovascular injury and cognitive impairment
    National Institute of Neurological Disorders and Stroke · 2022–2027
    R01NS126467-01
  • Co-I
    Contribution of G Protein Coupled Estrogen Receptor to Changes in Hypothalamic Plasticity and Hypertension Susceptibility in Mice with Accelerated Ovarian Failure
    National Heart, Lung, and Blood Institute · 2017–2026· 2 renewals
    R01HL136520-05A1
  • Co-I
    Tau-induced postsynaptic dysfunction in tauopathy models
    Cure Alzheimer’s Fund · 2023–2026
    CAF 233018-02
Completed grants (8)
  • Co-I
    Role of CaMKII-alpha ubiquitination in ischemic stroke
    National Institute of Neurological Disorders and Stroke · 2018–2024
    R01NS109588-05
  • Co-I
    Aberrant Prefrontal Cortical Plasticity and Neurobehavioral Consequences of Adolescent Marijuana
    National Institute on Drug Abuse · 2017–2023
    R01DA042943-05
  • Co-I
    Hypothalamic and metabolic dysfunction in Alzheimer's disease
    National Institute on Aging · 2021–2023
    R01AG070868-01
  • Co-I
    Hypothalamic Cytokines, Glutamate Receptor Plasticity, and Blood Pressure
    National Heart, Lung, and Blood Institute · 2017–2023
    R01HL135498-04
  • Co-I
    Hypertension and neurovascular dysfunction
    National Institute of Neurological Disorders and Stroke · 2019–2023
    R37NS089323-05
  • Co-I
    No Synthase Gene Expression and Cerebral Ischemic Damage
    National Institute of Neurological Disorders and Stroke · 2017–2023
    R01NS034179-26
  • Co-I
    ApoE4 and Mechanisms of Diffuse White Matter Injury
    National Institute of Neurological Disorders and Stroke · 2016–2022
    R01NS100447-01
  • KP
    Menopausal Changes in Hypothalamus and Hypertension Susceptibility
    National Heart, Lung, and Blood Institute · 2011–2016
    R01HL098351-04